Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Amani Therapeutics

Request full access

Safer combination therapies for serious neuropsychiatric disorders.

New York City, United StatesFounded 2026Biotech & Life Sciences

About Amani Therapeutics

Amani Therapeutics is a New York-based biotechnology company that launched in March 2026, focused on developing safer and more effective medicines for severe neuropsychiatric disorders. The company was established with the backing of RTW Investments, a global investment firm specializing in the biopharmaceutical and medical technology sectors. Upon its formation, Amani Therapeutics announced a $25 million Series A financing round.

The company's primary business revolves around its lead program, AM-01, a potential therapy for treatment-resistant schizophrenia. This condition represents a significant unmet need in the psychiatric market. Amani's core strategy involves improving upon existing effective treatments by mitigating their adverse side effects. The business model is centered on the clinical development and subsequent commercialization of its proprietary drug candidates. Amani generates value by acquiring and developing promising pharmaceutical assets.

AM-01 is a fixed-dose combination product that includes clozapine and a novel chemical entity (NCE) for which Amani has in-licensed worldwide rights from AstraZeneca. Clozapine is recognized as the most effective medication for treatment-resistant schizophrenia and for reducing suicide risk in patients with schizophrenia and schizoaffective disorder. However, its use is severely limited due to the risk of severe neutropenia, a dangerous drop in white blood cells, which requires patients to undergo frequent and burdensome blood monitoring. Amani's product, AM-01, aims to deliver clozapine's efficacy while addressing this major safety liability. The in-licensed NCE is Phase 3-ready, which may streamline the clinical development pathway for AM-01.

Amani Therapeutics is led by a team of experienced executives. Rob Swoboda serves as Chief Operating Officer, bringing operational and commercialization experience from roles at Karuna Therapeutics, bluebird bio, and Vertex Pharmaceuticals. Dr. Carla Canuso, the Chief Medical Officer, has over two decades of experience in neuropsychiatric clinical development at Johnson & Johnson, where she led the development team for intranasal esketamine.

Source: Dealroom company data

At a glance

Status
Operational
Employees
8
Open positions
None listed
Dealroom signal
45.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Psychology, Drug Development, Neurology, Mental Health, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Mar 2026 $25M $100M Undisclosed ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Amani Therapeutics website traffic

Latest recorded traffic for Amani Therapeutics is 780 monthly website visits.

Latest monthly visits780
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
HMNC Brain HealthThe company is developing therapeutics for the treatment of neuropsychiatric disorders with a focus on depression. These are to consist of patented genetic tests, licensed drugs and companion diagnostics with machine learning Munich, Germany Operational 27 $88M $200M
Transcend TherapeuticsDeveloping the next generation of psychoactive compounds for neuropsychiatry focused on patient access New York City, United States Acquired
Alto NeuroscienceClinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform Los Altos, United States Operational
COMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions London, United Kingdom Operational
PharnextDevelopment of treatments for severe neurological diseases Paris, France Closed
Syndeio BiosciencesDeveloping rapid-acting therapies to enhance synaptic health and treat CNS disorders through novel synapse pharmacology Indianapolis, United States Operational
Feel TherapeuticsFeel Therapeutics is the Digital Precision Medicine company for mental and behavioral health. We translate passive monitoring data into insights and enable precise interventions San Francisco, United States Operational
Firefly NeuroscienceElectro-physiology based functional brain mapping, imaging and monitoring technology Buffalo, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Amani Therapeutics in the New York City ecosystem

Live from Dealroom

The Amani Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Amani Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amani Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.